Organ Repair & Regeneration
PRO-303 is the first product candidate from the R-VEC platform. Reprogrammed vascular endothelial cells will offer the first cell replacement therapy with full natural vascularization.
.svg)
Proterris is advancing a pipeline focused on organ
preservation, repair & regeneration
PRO-301 is a P2b-ready therapeutic to improve outcomes in kidney transplant recipients, Supported by >$30M in NIH/DoD Awards to develop delivery devices & conduct P1/2a trials in IPF, ARDS & PAH
PRO-304 is a 510(k) candidate to improve current organ perfusion solutions by demonstrating better organ preservation, post-transplant function, and potentially expanding the pool of eligible donor organs
PRO-303 is the first product candidate from the R-VEC platform. Reprogrammed vascular endothelial cells will offer the first cell replacement therapy with full natural vascularization.
